RuPAC2021 - List of Authors (Lunev, P.A.)

Paper	Title	Page
FRB05	Updated Status of Protom Synchrotrons for Radiation Therapy	120
	A.A. Pryanichnikov, V. Alexandrov, V.E. Balakin, A.I. Bazhan, Belikhin, M.A. Belikhin, V.I. Chashurin, P.A. Lunev, A.E. Shemyakov, A.I. Shestopalov PhTC LPI RAS, Protvino, Russia V. Alexandrov, V.E. Balakin, A.I. Bazhan, Belikhin, M.A. Belikhin, P.A. Lunev, A.A. Pryanichnikov, A.E. Shemyakov, A.I. Shestopalov Protom Ltd., Protvino, Russia
	Physical-Technical Center of P.N. Lebedev Physical Institute of RAS and Protom Ltd. are engaged in development and implantation of synchrotrons for proton therapy into clinical practice. There are two proton therapy complexes "Prometheus" in Russia. That are fully developed and manufactured at Physical-Technical Center and Protom. Every day patients with head and neck cancer get treatment using "Prometheus" at the A. Tsyb Medical Radiological Research Center. At the moment these facilities together have accumulated more than 5 years of clinical experience. Two facilities are based on the Protom synchrotrons in the USA. One operates at the McLaren Hospital PT Center, it started to treat patients in 2018. Another one is as a part of the single-room proton therapy system "Radiance330" in Massachusetts General Hospital, that went into clinical operations in 2020. The first Israel proton therapy complex based on Protom synchrotron was launched in 2019. Protom facilities provide full stack of modern proton therapy technologies such as IMPT and pencil beam scanning. Key features of Protom synchrotron: low weight, compact size and low power consumption allow it to be placed in conventional hospitals without construction of any special infrastructure. This report presents current data on accelerator researches and developments of Physical-Technical Center and Protom Ltd. In addition, it provides data on the use of Protom based proton therapy complexes under the clinical conditions.
	Slides FRB05 [8.949 MB]
DOI •	reference for this paper ※ doi:10.18429/JACoW-RuPAC2021-FRB05
About •	Received ※ 19 September 2021 — Revised ※ 30 September 2021 — Accepted ※ 09 October 2021 — Issued ※ 11 October 2021
Cite •	reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)

Paper

Title

Page

Updated Status of Protom Synchrotrons for Radiation Therapy

120

A.A. Pryanichnikov, V. Alexandrov, V.E. Balakin, A.I. Bazhan, Belikhin, M.A. Belikhin, V.I. Chashurin, P.A. Lunev, A.E. Shemyakov, A.I. Shestopalov
PhTC LPI RAS, Protvino, Russia
V. Alexandrov, V.E. Balakin, A.I. Bazhan, Belikhin, M.A. Belikhin, P.A. Lunev, A.A. Pryanichnikov, A.E. Shemyakov, A.I. Shestopalov
Protom Ltd., Protvino, Russia

Physical-Technical Center of P.N. Lebedev Physical Institute of RAS and Protom Ltd. are engaged in development and implantation of synchrotrons for proton therapy into clinical practice. There are two proton therapy complexes "Prometheus" in Russia. That are fully developed and manufactured at Physical-Technical Center and Protom. Every day patients with head and neck cancer get treatment using "Prometheus" at the A. Tsyb Medical Radiological Research Center. At the moment these facilities together have accumulated more than 5 years of clinical experience. Two facilities are based on the Protom synchrotrons in the USA. One operates at the McLaren Hospital PT Center, it started to treat patients in 2018. Another one is as a part of the single-room proton therapy system "Radiance330" in Massachusetts General Hospital, that went into clinical operations in 2020. The first Israel proton therapy complex based on Protom synchrotron was launched in 2019. Protom facilities provide full stack of modern proton therapy technologies such as IMPT and pencil beam scanning. Key features of Protom synchrotron: low weight, compact size and low power consumption allow it to be placed in conventional hospitals without construction of any special infrastructure. This report presents current data on accelerator researches and developments of Physical-Technical Center and Protom Ltd. In addition, it provides data on the use of Protom based proton therapy complexes under the clinical conditions.

Slides FRB05 [8.949 MB]

DOI •

reference for this paper ※ doi:10.18429/JACoW-RuPAC2021-FRB05

About •

Received ※ 19 September 2021 — Revised ※ 30 September 2021 — Accepted ※ 09 October 2021 — Issued ※ 11 October 2021

Cite •

reference for this paper using ※ BibTeX, ※ LaTeX, ※ Text/Word, ※ RIS, ※ EndNote (xml)